vorinostat has been researched along with Neoplasm Metastasis in 20 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer." | 9.13 | A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. ( Aparicio, A; Doroshow, JH; Frankel, P; Gandara, DR; Leong, L; Lim, D; Luu, TH; McNamara, M; Morgan, RJ; Portnow, J; Smith, DD; Somlo, G; Wong, C, 2008) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 7.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| "The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer." | 5.13 | A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. ( Aparicio, A; Doroshow, JH; Frankel, P; Gandara, DR; Leong, L; Lim, D; Luu, TH; McNamara, M; Morgan, RJ; Portnow, J; Smith, DD; Somlo, G; Wong, C, 2008) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 3.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| "Vorinostat is a histone deacetylase inhibitor (HDACi)." | 2.84 | A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. ( Barrett, MT; Boerner, SA; Casetta, L; Chao, J; Chen, A; Goncalves, PH; Hansen, AR; Heilbrun, LK; Kummar, S; Lenkiewicz, E; LoRusso, PM; Malasi, S; Piekarz, RL; Pilat, MJ; Siu, LL; Smith, DW; Sukari, AW, 2017) |
| "Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients." | 2.73 | Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. ( Blumenschein, GR; Chen, C; Chiao, JH; Frankel, SR; Kies, MS; Kumar, AJ; Lu, C; Papadimitrakopoulou, VA; Ricker, JL, 2008) |
| "However, the role of Rnd1 in hepatocellular carcinoma (HCC) progression remains unclear." | 1.48 | The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. ( Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD, 2018) |
| "Metastasis is the reason for most cancer death, and a crucial primary step for cancer metastasis is invasion of the surrounding tissue, which may be initiated by some rare tumor cells that escape the heterogeneous primary tumor." | 1.43 | Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. ( Chen, X; Deng, Q; Feng, J; Guo, C; Huang, H; Ma, S; Shen, B; Wu, K; Wu, Z; Xia, B; Zhang, J; Zhang, K; Zhang, S; Zhu, L, 2016) |
| "Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis." | 1.42 | Histone deacetylase inhibitor for NUT midline carcinoma. ( Bell, D; Christensen, AM; Maher, OM; Tarek, N; Yedururi, S, 2015) |
| "SAHA inhibited tumor progression and metastasis in the murine xenograft model." | 1.40 | Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. ( Fujiwara, S; Goshima, F; Imadome, K; Iwata, S; Kanazawa, T; Kimura, H; Murata, T; Nakagawa, H; Siddiquey, MN; Suzuki, M, 2014) |
| "Using an experimental metastasis mouse model, we further demonstrated that decitabine and vorinostat cooperate to suppress colon carcinoma metastasis." | 1.38 | Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. ( Bardhan, K; Liu, K; McGaha, TL; Torres, CM; Yang, D; Zimmerman, M, 2012) |
| "Progression of prostate cancer following castration is associated with increased androgen receptor (AR) expression and signaling despite AR blockade." | 1.36 | Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. ( Coleman, IM; Haugk, K; Mostaghel, EA; Nelson, PS; Nguyen, HM; Page, ST; Plymate, SR; Soriano, K; Sprenger, CC; Sun, H; Sun, S; Vessella, RL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gray, JE | 1 |
| Saltos, A | 1 |
| Tanvetyanon, T | 1 |
| Haura, EB | 1 |
| Creelan, B | 1 |
| Antonia, SJ | 1 |
| Shafique, M | 1 |
| Zheng, H | 1 |
| Dai, W | 1 |
| Saller, JJ | 1 |
| Chen, Z | 1 |
| Tchekmedyian, N | 1 |
| Goas, K | 1 |
| Thapa, R | 1 |
| Boyle, TA | 1 |
| Chen, DT | 1 |
| Beg, AA | 1 |
| Rodriguez, CP | 1 |
| Wu, QV | 1 |
| Voutsinas, J | 1 |
| Fromm, JR | 1 |
| Jiang, X | 1 |
| Pillarisetty, VG | 1 |
| Lee, SM | 1 |
| Santana-Davila, R | 1 |
| Goulart, B | 1 |
| Baik, CS | 1 |
| Chow, LQM | 1 |
| Eaton, K | 1 |
| Martins, R | 1 |
| Goncalves, PH | 1 |
| Heilbrun, LK | 1 |
| Barrett, MT | 1 |
| Kummar, S | 1 |
| Hansen, AR | 1 |
| Siu, LL | 1 |
| Piekarz, RL | 1 |
| Sukari, AW | 1 |
| Chao, J | 1 |
| Pilat, MJ | 1 |
| Smith, DW | 1 |
| Casetta, L | 1 |
| Boerner, SA | 1 |
| Chen, A | 1 |
| Lenkiewicz, E | 1 |
| Malasi, S | 1 |
| LoRusso, PM | 1 |
| Peela, N | 1 |
| Barrientos, ES | 1 |
| Truong, D | 1 |
| Mouneimne, G | 1 |
| Nikkhah, M | 1 |
| Li, Q | 1 |
| Ding, C | 1 |
| Meng, T | 1 |
| Lu, W | 1 |
| Liu, W | 1 |
| Hao, H | 1 |
| Cao, L | 1 |
| Qin, CD | 1 |
| Ma, DN | 1 |
| Zhang, SZ | 1 |
| Zhang, N | 1 |
| Ren, ZG | 1 |
| Zhu, XD | 1 |
| Jia, QA | 1 |
| Chai, ZT | 1 |
| Wang, CH | 1 |
| Sun, HC | 1 |
| Tang, ZY | 1 |
| Liu, S | 1 |
| Li, F | 1 |
| Pan, L | 1 |
| Yang, Z | 1 |
| Shu, Y | 1 |
| Lv, W | 1 |
| Dong, P | 1 |
| Gong, W | 1 |
| Siddiquey, MN | 1 |
| Nakagawa, H | 1 |
| Iwata, S | 1 |
| Kanazawa, T | 1 |
| Suzuki, M | 1 |
| Imadome, K | 1 |
| Fujiwara, S | 1 |
| Goshima, F | 1 |
| Murata, T | 1 |
| Kimura, H | 1 |
| Maher, OM | 1 |
| Christensen, AM | 1 |
| Yedururi, S | 1 |
| Bell, D | 1 |
| Tarek, N | 1 |
| Mu, X | 1 |
| Brynien, D | 1 |
| Weiss, KR | 1 |
| Patel, S | 1 |
| Hurez, V | 1 |
| Nawrocki, ST | 1 |
| Goros, M | 1 |
| Michalek, J | 1 |
| Sarantopoulos, J | 1 |
| Curiel, T | 1 |
| Mahalingam, D | 1 |
| Zhang, S | 1 |
| Wu, K | 1 |
| Feng, J | 1 |
| Wu, Z | 1 |
| Deng, Q | 1 |
| Guo, C | 1 |
| Xia, B | 1 |
| Zhang, J | 1 |
| Huang, H | 1 |
| Zhu, L | 1 |
| Zhang, K | 1 |
| Shen, B | 1 |
| Chen, X | 1 |
| Ma, S | 1 |
| Thapa, RK | 1 |
| Nguyen, HT | 1 |
| Jeong, JH | 1 |
| Shin, BS | 1 |
| Ku, SK | 1 |
| Choi, HG | 1 |
| Yong, CS | 1 |
| Kim, JO | 1 |
| Woyach, JA | 1 |
| Kloos, RT | 1 |
| Ringel, MD | 1 |
| Arbogast, D | 1 |
| Collamore, M | 1 |
| Zwiebel, JA | 1 |
| Grever, M | 1 |
| Villalona-Calero, M | 1 |
| Shah, MH | 1 |
| Luu, TH | 1 |
| Morgan, RJ | 1 |
| Leong, L | 1 |
| Lim, D | 1 |
| McNamara, M | 1 |
| Portnow, J | 1 |
| Frankel, P | 1 |
| Smith, DD | 1 |
| Doroshow, JH | 1 |
| Wong, C | 1 |
| Aparicio, A | 1 |
| Gandara, DR | 1 |
| Somlo, G | 1 |
| Krejsgaard, T | 1 |
| Kopp, K | 1 |
| Ralfkiaer, E | 1 |
| Willumsgaard, AE | 1 |
| Eriksen, KW | 1 |
| Labuda, T | 1 |
| Rasmussen, S | 1 |
| Mathiesen, AM | 1 |
| Geisler, C | 1 |
| Lauenborg, B | 1 |
| Becker, JC | 1 |
| Zhang, Q | 1 |
| Wasik, MA | 1 |
| Odum, N | 1 |
| Woetmann, A | 1 |
| Sun, S | 1 |
| Sprenger, CC | 1 |
| Vessella, RL | 1 |
| Haugk, K | 1 |
| Soriano, K | 1 |
| Mostaghel, EA | 1 |
| Page, ST | 1 |
| Coleman, IM | 1 |
| Nguyen, HM | 1 |
| Sun, H | 1 |
| Nelson, PS | 1 |
| Plymate, SR | 1 |
| Wong, NS | 1 |
| Seah, EZh | 1 |
| Wang, LZ | 1 |
| Yeo, WL | 1 |
| Yap, HL | 1 |
| Chuah, B | 1 |
| Lim, YW | 1 |
| Ang, PC | 1 |
| Tai, BC | 1 |
| Lim, R | 1 |
| Goh, BC | 1 |
| Lee, SC | 1 |
| Yang, D | 1 |
| Torres, CM | 1 |
| Bardhan, K | 1 |
| Zimmerman, M | 1 |
| McGaha, TL | 1 |
| Liu, K | 1 |
| Blumenschein, GR | 1 |
| Kies, MS | 1 |
| Papadimitrakopoulou, VA | 1 |
| Lu, C | 1 |
| Kumar, AJ | 1 |
| Ricker, JL | 1 |
| Chiao, JH | 1 |
| Chen, C | 1 |
| Frankel, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies[NCT02538510] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2015-10-08 | Completed | ||
| Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma[NCT00134043] | Phase 2 | 19 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Kaplan Meier methods will be used to estimate progression free survival. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Months (Mean) |
|---|---|
| Head and Neck Squamous Cell Carcinoma | 12.6 |
| Salivary Gland Carcinoma | 14.0 |
Toxicities will be summarized as the number and percentage of patients with each type of toxicity, per Criteria for Adverse Events version 4.0 (NCT02538510)
Timeframe: Up to 30 days after the completion of study treatment
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | ALT increase | Anorexia | Arthiritis | AST increase | Cough | Increased Creatinine | Dermatitis | Diarrhea | Fever with leukocytosis | Fatigue | Hyponatremia | Hypothyroidism | Colitis and Ileitis | Malaise | Nausea | Nephritis | Pneumonitis | Neuritis | Tracheitis/Epiglottitis | Vomiting | |
| Head and Neck Squamous Cell Carcinoma | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Salivary Gland Carcinoma | 1 | 1 | 1 | 1 | 1 | 0 | 5 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 2 |
Radiologic assessments of measurable disease will be performed using radiographic imaging. RECIST 1.1 and immune response criteria will be used to assess response to therapy. Responses will be summarized as frequencies and percentages. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| partial response | stable disease | progressive disease | |
| Head and Neck Squamous Cell | 8 | 8 | 5 |
| Salivary Gland Carcinoma | 4 | 13 | 6 |
"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., or similar definition that is accurate and appropriate." (NCT00134043)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| PR (Partial Response) | CR (Complete Response) | Stable disease | |
| DTCs (Well-differentiated Thyroid Carcinomas) | 0 | 0 | 56 |
| MTC (Medullary Thyroid Cancer) | 0 | 0 | 0 |
7 trials available for vorinostat and Neoplasm Metastasis
| Article | Year |
|---|---|
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2019 |
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2020 |
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Chromatin Assembly and Disassembly; Exome Sequencing; Female | 2017 |
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Enzy | 2009 |
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Fema | 2008 |
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Topics: Adult; Antineoplastic Agents; Asian People; Breast Neoplasms; Demography; Disease-Free Survival; Fem | 2011 |
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Capsules; Car | 2008 |
13 other studies available for vorinostat and Neoplasm Metastasis
| Article | Year |
|---|---|
Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diffusion; | 2017 |
Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
Topics: Butyrates; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Histone Deacetylase Inhibitors; Hi | 2017 |
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genet | 2018 |
BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Divisio | 2019 |
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Progres | 2014 |
Histone deacetylase inhibitor for NUT midline carcinoma.
Topics: Adolescent; Carcinoma; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mandibular | 2015 |
The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol | 2015 |
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Color | 2016 |
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cel | 2016 |
Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomi | 2017 |
A novel xenograft model of cutaneous T-cell lymphoma.
Topics: Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Transplantation; Disease Models, A | 2010 |
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Topics: Androgen Antagonists; Animals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hyd | 2010 |
Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; Antineoplastic Combined Chemothera | 2012 |